Date of Data Capture: 18/06/2020
Name: PRO MEDICUS LIMITED (PME)
Classification: Medical Software & Technology
Current Price: $26.76
Market Capitalisation: $2.89 B
Forecast EBITDA Growth: 22.81%
Yield Estimate: 0.46%
Consensus Price Target: $28.43
# Covering Analysts: 7
Discount at Current Price: -6.24%
Price Target Trend (3-Month): Up-Flat +1.90%
Signal Timeframe: Monthly-Weekly-Daily
Trend Bias: Up-Down / Long-Short
Focus: Capital Growth
Set up Notes:
· Health imaging technology specialist PME is currently climbing higher within a sharp recovery growth trend and offers a fresh entry here with good performance and forecasting.
· Strong sales, margins and earnings growth from 2015 rewarded shareholders well, but recent weakness should be a good buying opportunity with further strong growth expected out to 2022.
· Pricing shows an exponential rally reaching its blow-off top culmination by late 2019, before entering price consolidation (exacerbated by the Covid19 panic) but is now rallying again off deep support with positive momentum building here.
§ Support ($): 25.00, 22.50, 20.00, & 15.00.
§ Resistance ($): 30.00, 35.00, 37.50 & clear.